"Receptors, Complement 3b" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Molecular sites on or in some B-lymphocytes and macrophages that recognize and combine with COMPLEMENT C3B. The primary structure of these receptors reveal that they contain transmembrane and cytoplasmic domains, with their extracellular portion composed entirely of thirty short consensus repeats each having 60 to 70 amino acids.
| Descriptor ID |
D017463
|
| MeSH Number(s) |
D12.776.543.750.705.833.600
|
| Concept/Terms |
Receptors, Complement 3b- Receptors, Complement 3b
- Complement 3b Receptors
- C3b Receptors
- Receptors, C3b
- CD 35 Antigens
- Antigens, CD 35
- Antigens, CD35
- CD35 Antigens
- CR1 Receptors
- Receptors, CR1
- Complement 3b Receptor
- Receptor, Complement 3b
- CD35 Antigen
- Antigen, CD35
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Complement 3b".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Complement 3b".
This graph shows the total number of publications written about "Receptors, Complement 3b" by people in this website by year, and whether "Receptors, Complement 3b" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 3 | 3 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 1 | 1 | 2 |
| 2012 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 1 | 2 |
| 2018 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Complement 3b" by people in Profiles.
-
Characterization of Novel P-Selectin Targeted Complement Inhibitors in Murine Models of Hindlimb Injury and Transplantation. Front Immunol. 2021; 12:785229.
-
Increasing the efficacy and safety of a human complement inhibitor for treating post-transplant cardiac ischemia reperfusion injury by targeting to a graft-specific neoepitope. J Heart Lung Transplant. 2021 10; 40(10):1112-1121.
-
C2 IgM Natural Antibody Enhances Inflammation and Its Use in the Recombinant Single Chain Antibody-Fused Complement Inhibitor C2-Crry to Target Therapeutics to Joints Attenuates Arthritis in Mice. Front Immunol. 2020; 11:575154.
-
Sialic acid is a critical fetal defense against maternal complement attack. J Clin Invest. 2019 01 02; 129(1):422-436.
-
Targeting pathogenic postischemic self-recognition by natural IgM to protect against posttransplantation cardiac reperfusion injury. Circulation. 2015 Mar 31; 131(13):1171-80.
-
A new mouse anti-mouse complement receptor type 2 and 1 (CR2/CR1) monoclonal antibody as a tool to study receptor involvement in chronic models of immune responses and disease. Mol Immunol. 2015 Feb; 63(2):479-88.
-
Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA. Ann Rheum Dis. 2016 Jan; 75(1):242-52.
-
A new treatment for neurogenic inflammation caused by EV71 with CR2-targeted complement inhibitor. Virol J. 2012 Nov 23; 9:285.
-
Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol. 2010 Dec; 67(12):1473-84.
-
A new therapeutic strategy for lung tissue injury induced by influenza with CR2 targeting complement inhibitor. Virol J. 2010 Feb 09; 7:30.